Unclaimed brand
NanoCell Therapeutics is a privately-held biotechnology company with offices in King of Prussia, Pennsylvania, and Utrecht, the Netherlands. Our mission is to revolutionize in-vivo cell engineering through our groundbreaking non-viral, DNA-based gene therapy platform, primarily focusing on oncology and autoimmune diseases. At NanoCell, we’re driving innovation by transforming traditional adoptive cell therapy methods into advanced in-vivo treatments. Our ultimate goal is to simplify the treatment process, increasing patient accessibility, potential clinical benefits, and cost-effective manufacturing. We work both autonomously and in collaboration with partners to make substantial advancements in our targeted disease areas. For more information, visit http://www.nanocelltx.com).
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#C16031
Tuscany
193, 96, 49
20, 60, 47
0, 50, 75, 24
#E0AF98
Calico
224, 175, 152
19, 54, 74
0, 22, 32, 12
#005E6E
Blue Stone
0, 94, 110
189, 100, 22
100, 15, 0, 57
NanoCell Therapeutics is a biotechnology company developing in vivo gene therapies through a non-viral, DNA-based platform designed to direct therapeutic genetic material to specific cells inside the patient. Its proprietary delivery approach aims to offer an alternative to viral gene delivery methods and to transform adoptive cell therapies into gene therapies. The company’s goal is to improve the scalability, affordability, safety, and efficacy of cell and gene therapy, helping broaden patient access to treatment options.
Its technology portfolio includes NanoCAR, presented as part of its work in cell engineering and in vivo gene therapy. Rather than modifying cells outside the body, NanoCell’s approach is designed to engineer target cells within the patient. The company’s research and development activities are led by a team with experience in gene therapy, pharmaceutical development, preclinical research, finance, and intellectual property.
NanoCell Therapeutics describes its mission as advancing precise cell modification and developing therapeutic options for patients worldwide
